Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.500
+0.170 (3.93%)
Jul 13, 2026, 4:00 PM EDT - Market closed
Camp4 Therapeutics Employees
Camp4 Therapeutics had 48 employees as of December 31, 2025. The number of employees decreased by 7 or -12.73% compared to the previous year.
Employees
48
Change (1Y)
-7
Growth (1Y)
-12.73%
Revenue / Employee
$81,958
Profits / Employee
-$1,797,938
Market Cap
233.67M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 48 | -7 | -12.73% |
| Dec 31, 2024 | 55 | -9 | -14.06% |
| Sep 30, 2024 | 53 | -11 | -17.19% |
| Jun 30, 2024 | 58 | - | - |
| Dec 31, 2023 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Karyopharm Therapeutics | 228 |
| Codexis | 146 |
| Invivyd | 122 |
| Keros Therapeutics | 87 |
| Compugen | 75 |
| Precision BioSciences | 66 |
| Fulcrum Therapeutics | 55 |
CAMP News
- 12 days ago - X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board - TheFly
- 24 days ago - CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Camp4 Therapeutics upgraded to Overweight from Neutral at JPMorgan - TheFly
- 4 weeks ago - Camp4 Therapeutics Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Camp4 Therapeutics initiated with a Buy at Chardan - TheFly
- 5 weeks ago - New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity - GlobeNewsWire
- 7 weeks ago - CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder - GlobeNewsWire